NasdaqCM:VKTXBiotechs
Assessing Viking Therapeutics (VKTX) Valuation After VK2735 Phase 2 Success And Phase 3 Trial Progress
Why VK2735’s latest trial results matter for Viking Therapeutics (VKTX)
Viking Therapeutics (VKTX) is back in focus after publishing Phase 2 VENTURE trial results for its dual GLP-1/GIP candidate VK2735 and confirming full enrollment in two large Phase 3 obesity and diabetes studies.
See our latest analysis for Viking Therapeutics.
VKTX’s share price has been choppy around the latest VK2735 updates, with a 7 day share price return of 4.71% but a 30 day share price return of 8.32% and a year...